Strike Pharma develops individualized immunotherapeutic treatments using its proprietary Adaptable Drug Affinity Conjugate (ADAC™) technology, which targets tumor cells based on the genetic profile of each patient's tumor. This approach enhances therapeutic efficacy while minimizing side effects, addressing the limitations of traditional immunotherapy methods that often overlook efficient drug delivery and stability.
Funding
$6.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer immunotherapies often lack efficient drug delivery and in vivo stability, leading to limited clinical success and potential side effects due to off-target effects. These therapies may not effectively target tumor cells based on the unique genetic profile of each patient's tumor.
Solution
Strike Pharma is developing individualized immunotherapeutic treatments using its proprietary Adaptable Drug Affinity Conjugate (ADAC™) technology. This technology enables the creation of highly targeted treatments based on the genetic profile of each patient’s tumor, enhancing therapeutic efficacy. The ADAC™ technology aims to improve targeted delivery and in vivo stability, addressing the limitations of current immunotherapeutic approaches. By focusing on precision medicine, Strike Pharma aims to increase therapeutic efficacy and reduce dosage levels, thereby minimizing the risk of side effects.
Target Audience
Strike Pharma's primary target audience includes cancer patients and healthcare providers seeking more effective and personalized immunotherapeutic treatments.
Features
- Adaptable Drug Affinity Conjugate (ADAC™) technology for individualized cancer immunotherapy
- Tumor-specific targeting based on the genetic profile of each patient's tumor
- Enhanced drug delivery and in vivo stability
- Potential for increased therapeutic efficacy
- Reduced dosage levels to minimize the risk of side effects